Pantothenate Kinase-Associated Neurodegeneration (PKAN)

Pantothenate Kinase-Associated Neurodegeneration (PKAN)

Overview

Pantothenate Kinase-Associated Neurodegeneration (PKAN), formerly known as Hallervorden-Spatz syndrome, is a rare autosomal recessive neurodegenerative disorder and the most common form of neurodegeneration with brain iron accumulation (NBIA), accounting for approximately 35-50% of all NBIA cases[@pellecchia2020]. PKAN is caused by mutations in the PANK2 gene, which encodes the mitochondrial enzyme pantothenate kinase 2—the rate-limiting enzyme in coenzyme A (CoA) biosynthesis[@leone2019].

The disease is characterized by progressive movement disorders including dystonia, dysarthria, rigidity, and pigmentary retinal degeneration, with pathological iron accumulation primarily in the globus pallidus and substantia nigra pars reticulata. The clinical phenotype results from a combination of impaired CoA biosynthesis, mitochondrial dysfunction, iron-mediated oxidative damage, and potentially ferroptosis—a newly described form of iron-dependent cell death[@kristian2020].

Epidemiology

PKAN is a rare disorder with the following epidemiological characteristics:

• Incidence: 1-3 per million population worldwide
• Prevalence within NBIA: 35-50% of all NBIA cases
• Inheritance pattern: Autosomal recessive (both copies of PANK2 must be mutated)
• Gender distribution: Equal affected males and females
• Age of onset: Two main clinical forms
• Classic PKAN: Onset before age 6 (accounts for ~75% of cases)
• Atypical PKAN: Onset after age 10, typically in adolescence

Pantothenate Kinase-Associated Neurodegeneration (PKAN)

Overview

Pantothenate Kinase-Associated Neurodegeneration (PKAN), formerly known as Hallervorden-Spatz syndrome, is a rare autosomal recessive neurodegenerative disorder and the most common form of neurodegeneration with brain iron accumulation (NBIA), accounting for approximately 35-50% of all NBIA cases[@pellecchia2020]. PKAN is caused by mutations in the PANK2 gene, which encodes the mitochondrial enzyme pantothenate kinase 2—the rate-limiting enzyme in coenzyme A (CoA) biosynthesis[@leone2019].

The disease is characterized by progressive movement disorders including dystonia, dysarthria, rigidity, and pigmentary retinal degeneration, with pathological iron accumulation primarily in the globus pallidus and substantia nigra pars reticulata. The clinical phenotype results from a combination of impaired CoA biosynthesis, mitochondrial dysfunction, iron-mediated oxidative damage, and potentially ferroptosis—a newly described form of iron-dependent cell death[@kristian2020].

Epidemiology

PKAN is a rare disorder with the following epidemiological characteristics:

• Incidence: 1-3 per million population worldwide
• Prevalence within NBIA: 35-50% of all NBIA cases
• Inheritance pattern: Autosomal recessive (both copies of PANK2 must be mutated)
• Gender distribution: Equal affected males and females
• Age of onset: Two main clinical forms
• Classic PKAN: Onset before age 6 (accounts for ~75% of cases)
• Atypical PKAN: Onset after age 10, typically in adolescence

Genetics and Molecular Basis

The PANK2 Gene

The PANK2 gene (Pantothenate Kinase 2) is located on chromosome 20p13 and contains 16 exons spanning approximately 21 kilobases of genomic DNA. The encoded protein consists of 691 amino acids with a molecular weight of approximately 78 kDa[@schneider2019].

Gene structure:

• Location: Chromosome 20p13
• Exons: 16
• Protein: 691 amino acids
• Subcellular localization: Mitochondrial matrix

Enzyme Function

PANK2 is the mitochondrial isoform of pantothenate kinase and catalyzes the first and rate-limiting step of coenzyme A (CoA) biosynthesis: the phosphorylation of pantothenate (vitamin B5) to 4'-phosphopantothenate. This enzymatic reaction requires ATP as a phosphate donor and represents the critical control point in the five-step CoA biosynthetic pathway.

CoA biosynthesis pathway:

PANK2 is essential for:

• Mitochondrial CoA synthesis
• Tricarboxylic acid (TCA) cycle function
• Fatty acid oxidation
• Mitochondrial membrane integrity
• Lysosomal function
• Cellular energy metabolism

Mutation Spectrum

Over 150 pathogenic PANK2 variants have been identified in patients with PKAN[@gregory2021]:

Types of mutations:

• Null (loss-of-function) mutations: Complete loss of PANK2 activity; typically associated with classic, severe PKAN phenotype
• Missense mutations: Residual enzyme activity preserved; more commonly associated with atypical PKAN
• Splice-site mutations: Often lead to truncated or unstable protein

Genotype-Phenotype Correlation

The relationship between PANK2 genotype and clinical phenotype is relatively well-characterized:

• Null mutations ( nonsense, frameshift): Typically cause classic, early-onset PKAN
• Missense mutations with residual activity: More commonly cause atypical, later-onset PKAN
• Compound heterozygosity: Phenotype depends on the combination of alleles

Pathophysiology

Coenzyme A Deficiency

The primary biochemical defect in PKAN is impaired CoA biosynthesis in mitochondria[@estevao2022]:

Consequence cascade:

Iron Accumulation

The hallmark neuropathological feature of PKAN is iron deposition in the globus pallidus and substantia nigra:

Mechanisms of iron accumulation:

• Selective vulnerability: Globus pallidus interna (GPi) and substantia nigra pars reticulata (SNr) are particularly affected
• Ferroptosis: Iron-dependent non-apoptotic cell death pathway now implicated
• Transferrin saturation: Possibly altered iron handling in affected neurons
• Dysregulation of iron storage proteins: Ferritin and other iron-handling proteins affected

• Excess iron catalyzes hydroxyl radical generation via Fenton chemistry
• Lipid peroxidation
• Protein oxidation
• DNA damage
• Membrane destruction

Mitochondrial Dysfunction

PANK2 deficiency directly impacts mitochondrial function[@krebs2021]:

• Impaired mitochondrial CoA synthesis reduces TCA cycle function
• Decreased beta-oxidation leads to lipid accumulation
• Reduced oxidative phosphorylation capacity
• Impaired mitochondrial dynamics (fusion/fission)
• Mitochondrial oxidative stress creates a degenerative feedback loop
• Energy failure in high-energy-demand neurons

Neuroaxonal Degeneration

Pathological studies reveal:

• Neuroaxonal dystrophy: Swollen, dystrophic axons (spheroids)
• Axonal degeneration: Progressive loss of neuronal processes
• Gliosis: Reactive astrocytosis in affected regions
• Neuronal loss: Death of projection neurons in globus pallidus and substantia nigra

Clinical Features

Classic PKAN

Accounts for approximately 75% of all PKAN cases[@gregory2021]:

Age of onset: Typically before age 6, most children present at 3-4 years

Initial symptoms:

• Gait disturbance (most common first symptom)
• Progressive dystonia, especially in lower extremities
• Difficulty with fine motor tasks
• Falls and clumsiness

• Rapid progression over 1-2 years
• Loss of ambulation typically within 1-2 years of onset
• Development of severe generalized dystonia
• Progressive bulbar dysfunction leading to speech and swallowing difficulties
• Cognitive decline in many patients

• Pigmentary retinopathy: Progressive visual impairment due to retinal degeneration
• "Eye of the tiger" sign: MRI finding (see Diagnosis section)
• Dysarthria: Often severe, with virtually incomprehensible speech
• Intellectual disability: Variable, but many patients show cognitive impairment

Atypical PKAN

Accounts for approximately 25% of cases:

Age of onset: After age 10, most commonly in adolescence (10-18 years)

Disease progression:

• Slower, more gradual decline
• Disease may stabilize for periods
• Survival into adulthood is common

• Less severe dystonia than classic PKAN
• Speech difficulties (dysarthria) are very common
• Psychiatric manifestations (depression, anxiety) may be prominent
• Some patients develop pigmentary retinopathy but less common
• Parkinsonism features (bradykinesia, rigidity) may be present

Core Symptoms Across Both Forms

Movement disorders:

• Progressive dystonia (most prominent and disabling symptom)
• Rigidity
• Tremor (less common)
• Chorea (rare)
• Ataxia (variable)

• Dysarthria (speech difficulties)
• Dysphagia (swallowing difficulties)
• Cognitive impairment
• Psychiatric symptoms (depression, anxiety, OCD-like behaviors)

• Pigmentary retinal degeneration
• Progressive vision loss
• Optic atrophy (in some cases)

Diagnosis

Clinical Presentation

The diagnosis of PKAN is based on a combination of clinical features, characteristic MRI findings, and genetic confirmation:

Suspicion criteria:

• Progressive movement disorder with dystonia in a child or adolescent
• Characteristic MRI findings ("eye of the tiger" sign)
• Family history consistent with autosomal recessive inheritance
• Pigmentary retinopathy

"Eye of the Tiger" Sign

The distinctive MRI finding in PKAN is considered a hallmark diagnostic marker[@martin2020]:

Description:

• Central hyperintense area in the globus pallidus on T2-weighted MRI
• Surrounded by a hypointense rim (iron deposition)
• Creates an appearance reminiscent of a tiger's eye

• Present in approximately 90% of classic PKAN cases
• Less common in atypical PKAN
• Reflects iron deposition (hypointense) with central gliosis or cystic change (hyperintense)

• T2-weighted imaging is most sensitive
• Particularly evident in coronal and axial planes
• May be less prominent on T1-weighted images

Genetic Testing

PANK2 sequencing:

• Direct sequencing of the PANK2 gene confirms the diagnosis
• Identifies pathogenic variants in >90% of clinically diagnosed cases
• Should include full gene sequencing and deletion/duplication analysis

• Available for families with known mutations
• Important for genetic counseling

• Possible for families with known PANK2 mutations
• Used for at-risk pregnancies

Diagnostic Workup

| Test | Finding in PKAN |
|------|-----------------|
| Brain MRI | "Eye of the tiger" sign in globus pallidus |
| PANK2 genetic testing | Biallelic pathogenic variants |
| Fundoscopic exam | Pigmentary retinopathy (most common in classic) |
| Ocular coherence tomography | Retinal layer thinning |
| EEG | May show generalized slowing |
| neuropsychological testing | Variable cognitive impairment |

Differential Diagnosis

Other NBIA disorders must be considered:

• PLAN (Phospholipase A2, group VI): PLA2G6 mutations
• MPAN (Mitochondrial Membrane Protein-Associated Neurodegeneration): C19orf12 mutations
• FA2H (Fatty Acid 2-Hydroxylase): FA2H mutations
• CoPAN (COASY Protein-Associated Neurodegeneration): COASY mutations
• NBIA1 (PKAN): PANK2 (most common)

• Dystonia responsive to dopaminergic medications (DYT5/tyrosine hydroxylase deficiency)
• Cerebral palsy
• Other metabolic disorders

Treatment

Disease-Modifying Approaches

Current disease-modifying strategies are limited but actively being investigated[@marshall2023]:

CoA pathway intermediates:

• Pantothenate (vitamin B5) supplementation: Trials showed limited efficacy
• CoA biosynthetic intermediates: Under investigation
• Pankrin (pantethine): Investigational

• Deferoxamine: Limited benefit, controversial efficacy
• Other chelators: Not proven effective for neurological symptoms

• Small molecule PANK2 activators: In preclinical/early clinical development
• Gene therapy: AAV-based approaches in preclinical development[@zhang2022]
• Enzyme replacement: Not yet available
• Metabolic rescue strategies: Under investigation

Symptomatic Management

Movement disorders:

• Botulinum toxin injections: For focal dystonia
• Deep brain stimulation (DBS): Very effective for severe dystonia; targets GPi
• Anticholinergics (trihexyphenidyl): May reduce dystonia
• Benzodiazepines (diazepam, clonazepam): Muscle relaxant effect
• Dopamine antagonists: May help in some cases
• Tetrabenazine: For choreiform movements

• Speech therapy
• Augmentative and alternative communication (AAC) devices

• Coenzyme A precursors (pantethine)
• Vitamin supplementation
• Tube feeding may be required for dysphagia

• Maintain function and mobility
• Prevent contractures
• Adaptive equipment for ADLs

Emerging Therapies

Clinical trials:

• PANK2 activator studies
• Gene therapy trials (AAV-PANK2)
• Natural history studies ongoing

• Biomarker development for clinical trials
• Outcome measure validation
• Early intervention strategies

Animal Models

Mouse Models

Several mouse models of PKAN have been developed:

• Pank2 knockout mice: Show biochemical and some phenotypic features of PKAN
• Pank2 conditional knockouts: Brain-specific deletion
• Zebrafish models: Phenotype characteristics for drug screening

Models Recapitulate

• Reduced CoA levels in affected tissues
• Iron accumulation in brain
• Movement deficits
• Mitochondrial dysfunction

NBIA Spectrum

PKAN is part of a broader group of disorders characterized by brain iron accumulation (NBIA):

| NBIA Type | Gene | Key Features |
|-----------|------|---------------|
| PKAN | PANK2 | Most common; eye of tiger sign |
| PLAN | PLA2G6 | Early onset, axonal dystrophy |
| MPAN | C19orf12 | Adult onset, neuropsychiatric features |
| FA2H | FA2H | Childhood onset, ataxia |
| CoPAN | COASY | Adult onset |
| BPAN | WDR45 | X-linked, treatable with iron chelation |

Research Directions

Current Research Priorities

• Understanding genotype-phenotype correlations in detail
• Developing PANK2-targeted small molecule therapies
• Optimizing gene therapy approaches
• Biomarker development for clinical trials
• Natural history studies to define outcome measures
• Understanding the role of ferroptosis in disease pathogenesis
• Identifying early biomarkers for pre-symptomatic intervention

Clinical Trial Readiness

• Validated clinical outcome measures (BFM dystonia scale, Burke-Fahn-Marsden Dystonia Rating Scale)
• MRI biomarkers (iron deposition quantification)
• Biochemical biomarkers (CoA pathway metabolites)
• Patient registries (NBIA Alliance)

See Also

• [NBIA Spectrum](/diseases/nbia-spectrum)
• [PANK2 Gene](/genes/pank2)
• [Coenzyme A Pathway](/mechanisms/coenzyme-a-biosynthesis)
• [Neurodegeneration with Brain Iron Accumulation](/diseases/nbia)
• [Dystonia](/mechanisms/dystonia-movement-disorder)
• [Ferroptosis](/mechanisms/ferroptosis-neurodegeneration)
• [Mitochondrial Dysfunction](/mechanisms/mitochondrial-dysfunction-neurodegeneration)

Key Publications

External Links

• [NBIA Disorders Association](https://nbiausa.org/)
• [NINDS NBIA Information](https://www.ninds.nih.gov/health-information/disorders/neurodegeneration-brain-iron-accumulation-nbia)
• [GeneReviews: PANK2-Related Neurodegeneration](https://www.ncbi.nlm.nih.gov/books/NBK1498/)
• [OMIM: PKAN](https://www.omim.org/entry/234200)
• [ClinicalTrials.gov - PKAN](https://clinicaltrials.gov/search?cond=PKAN)
• [PANK2 Foundation](https://www.pkan.org/)

References